Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab vs Pembrolizumab in 1L Metastatic NSCLC with High PD-L1
NCT06767514Phase 3Recruiting
- Sponsor
- Summit Therapeutics
- Start
- Feb 2025
- Primary completion
- Apr 2028
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Summit Therapeutics. Primary endpoints: Overall Survival at 36 months and Progression-Free Survival at 36 months. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06767514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767514.